Hot Features
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release... Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.8 | 50.4504504505 | 5.55 | 8.7 | 5.55 | 7506677 | 7.67704362 | DE |
| 4 | 3.85 | 85.5555555556 | 4.5 | 8.7 | 4.3 | 2844232 | 6.86900217 | DE |
| 12 | 4.25 | 103.658536585 | 4.1 | 8.7 | 4.1 | 1655211 | 5.82220378 | DE |
| 26 | 4.7 | 128.767123288 | 3.65 | 8.7 | 3.65 | 1434056 | 5.12398352 | DE |
| 52 | 4.95 | 145.588235294 | 3.4 | 8.7 | 2.55 | 1436671 | 4.2748764 | DE |
| 156 | 0.25 | 3.08641975309 | 8.1 | 15.7 | 2.4 | 1498152 | 6.92944154 | DE |
| 260 | -2.65 | -24.0909090909 | 11 | 15.7 | 2.4 | 1410898 | 7.31043892 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.